The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women

Atherosclerosis Supplements

Volumn 3, Issue 1, 2002, Pages 53-63

  Seed, Mary ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Coronary heart disease (CHD); Hormone replacement therapy (HRT); Lipids; Statins; Women

Indexed keywords

CONJUGATED ESTROGEN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE; PLACEBO; PRAVASTATIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; MEVINOLIN;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG CHOICE; DRUG EFFECT; DRUG USE; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; FEMALE; LIPID METABOLISM; MORTALITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPID METABOLISM; LOVASTATIN; POSTMENOPAUSE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0036581541     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(01)00009-5     Document Type: Conference Paper

References (89)

1. Lerner D.J., Kannel W.B. Patterns of coronary heart disease morbidity in the sexes: a 26 year follow-up of the Framingham population. Am. Heart J. 316:1986;1105-1110.
2. Gordon T., Kannel W.B., Hjortland M.C., McNamara P.M. Menopause and coronary heart disease: The Framingham Study. Ann. Intern. Med. 89:1978;157-161.
3. Bush T.L., Barrett-Connor E., Cowan L.D., et al. Cardiovascular mortality and non-contraceptive use of estrogen in women: results from the Lipid Research Clinics Programme Follow-up study. Circulation. 75:1987;1102-1109.
4. The Lipid Research Clinics Programme Epidemiology Committee. Plasma lipid distributions in selected North American populations. The Lipid Research Clinics programme prevalence study. Circulation 1979;60:427-39.
5. Matthews K.A., Meilahn E., Kuller L.H., et al. Menopause and risk factors for coronary heart disease. New Engl. J. Med. 321:1989;641-646.
6. Stevenson J.C., Crook D., Godsland I.F. Effects of age and menopause on lipid metabolism in healthy women. Atherosclerosis. 98:1993;83-90.
7. Miller G.J., Miller N.E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart disease. Lancet. 1:1975;16-19.
8. Tikkanen M.J., Nikkila E.A., Kuusi T., et al. Differential effects of two progestins on plasma high density lipoprotein (HDL2) and post heparin plasma hepatic lipase activity. Atherosclerosis. 40:1981;365-369.
9. Shepherd J., Packard C.J., Patsch J.R., et al. Metabolism of apolipoprotein AI and AII and its influence on the high density lipoprotein subfraction distribution in males and females. Eur. J. Clin. Invest. 8:1978;115-120.
10. Fahreus L., Larsson-Cohn U., Wallentin L. 1-Norgestrel and progesterone have different influences on plasma lipoproteins. Eur. J. Clin. Invest. 13:1983;447-453.
11. Effects of oestrogen or estrogen/progestin regimens on heart disease risk factors in menopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J. Am. Med. Assoc. 273:1995;199-208.
12. Van der Mooren M.J., Demacker P.N.M., Thomas C.M.G., Rolland R. Beneficial effect on serum lipoproteins by 17-oestradiol-dydrogesterone therapy in postmenopausal women: a prospective study. Eur. J. Obstet. Gynecol. Reprod. Biol. 47:1992;153-160.
13. Glueck C.J., Scheel D., Fishback J., Steiner P. Estrogen-induced pancreatitis in patients with previously covert familial type V hyperlipoproteinemia. Metabolism. 22:1972;807-814.
14. Crook D., Cust M.P., Gangar K.F., et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am. J. Obstet. Gynecol. 166:1992;950-955.
15. Plow E.F., Miles L.A. Scanu A.M. Relationship between plasminogen receptors and Lp(a). Lipoprotein(a). 8:1990;117-126 Academic Press, New York.
16. Soma M., Osnago-Gadda I., Paoletti R., Fumagalli R., et al. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch. Intern. Med. 153:1993;1462-1468.
17. Walton C., Godsland I.F., Proudler A.J., Wynn V., et al. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur. J. Clin. Invest. 23:1993;466-473.
18. Barrett-Connor E., Laakso M. Ischaemic heart disease risk in postmenopausal women. Effects of oestrogen use on glucose and insulin levels. Arteriosclerosis. 10:1990;531-534.
19. Lobo R.A., Pickar J.H., Wild R.A., Walsh B., Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated oestrogen therapy in postmenopausal women. The Menopause Study Group. Obstet. Gynaec. 84:1994;987-995.
20. Espeland M.A., Hogan P.E., Fineberg S.E., Howard G., Schrott H., Waclawin M.A., Bush T.L. Effect of postmenopausal hormone replacement therapy on glucose and insulin concentrations. Diabetes Care. 21:1998;1589-1595.
21. Smith M.R., Feher M. Hormone replacement therapy, cardiovascular risk factors and diabetes. J. Br. Menopause Soc. 6:2000;94-97.
22. Brussard H.E., Gevers Leuven J.A., Frolich M., Kluft C., et al. Short-term oestrogen replacement therapy improves insulin resistance, lipids, and fibrinolysis in postmenopausal women with NIDDM. Diabetologia. 40:1997;843-849.
23. Andersson B., Mattsson L.A., Hahn L., Marin P., et al. Oestrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in post-menopausal women with non-insulin dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;638-643.
24. Seed M., Mandeno R., Dornhorst A., Darko D.A. The effect of route of administration of hormone replacement therapy on cardiovascular risk factors in normal and type 2 diabetic women. J. Br. Menopause Soc. S3:2000;23.
25. Sack M.N., Rader D.J., Cannon R.O. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 343:1994;269-270.
26. Wagner J.D., St Clair R.W., Schwenkle D.C., Shively C.A., et al. Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys. Arterioscler. Thromb. 12:1992;717-725.
27. Adams M.R., Register T.C., Golden D.L., Wagner J.D., et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;217-221.
28. Register T.C., Adams M.R., Golden D.L., Clarkson T.B. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodelling after plasma lipid lowering in female monkeys. Arterioscler. Thromb. Vasc. Biol. 18:1998;1164-1171.
29. Miyagawa K., Rosch J., Staneczyk F., Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat. Med. 3:1997;324-327.
30. Williams J.K., Adams M.R., Herrington D.M., Klopferstein H.S. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 81:1990;1680-1687.
31. Williams J.K., Adams M.R., Herrington D.M., Clarkson T.B. Short term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J. Am. Coll. Cardiol. 20:1992;452-457.
32. Collins P., Rosano G.M.C., Sarrel P.M., Ulrich L., Adamopoulos S., et al. Estradiol 17B attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 92:1995;5-8.
33. Jiang C., Poole-Wilson P.A., Sarrel P.M., Mochizuki S., et al. Effect of 17B-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. Br. J. Pharmacol. 106:1992;739-745.
34. Gangar K.F., Reid G.A., Crook D., Hillard T.C., Whitehead M.I. Oestrogens and atherosclerotic vascular disease - local vascular factors. Bailliere's Clin. Endocrinol. Metab. 7:1993;47-59.
35. Rosano G.M.C., Sarrel P.M., Poole-Wilson P.A., Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet. 342:1993;133-136.
36. Rosano G.M.C., Collins P., Kaski J.C., Lindsay D.C., et al. Syndrome X in women is associated with oestrogen deficiency. Eur. Heart J. 16:1995;610-614.
37. Gilligan D.M., Quyyumi A.A., Cannon R.O. III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 89:1994;2545-2551.
38. Herrington D.M., Braden G.A., Williams J.K., Morgan T.M. Endothelium-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am. J. Cardiol. 73:1994;951-952.
39. Weiner C.P., Lizasoam I., Baylis S.A., Knowles R.G., Charles I.G., Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc. Natl. Acad. Sci. USA. 91:1994;5212-5216.
40. Keanye J.F., Schwaery G.T., Xu A., Nicolosi R.J., et al. 17Beta estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolaemic swine. Circulation. 89:1994;2251-2259.
41. De Caterina R., Libby P., Peng H.B., Thannickal V.J., et al. Nitric oxide decreases cytokine-induced activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and pro-inflammatory cytokines. J. Clin. Invest. 96:1995;60-68.
42. Kirk G., McLaren M., Roberts K., Belch J.I.F., Seed M. Elevated levels of E-Selectin in post menopausal females are decreased by hormone replacement therapy to levels observed in pre-menopausal females. Thromb. Haemost. 82:1999;1433-1436.
43. Gebara O.C.E., Mittleman M.A., Sutherland P., et al. Association between increased estrogen and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 91:1995;1952-1958.
44. Koh K.K., Mincemoyer R., Bui M.N., Csako G., et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. New Engl. J. Med. 336:1997;683-690.
45. Mitrio V., Marino R., Cicnelli E., Galantino P., et al. Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C. Blood Coagul. Fibrinolysis. 11:(1):2000;75-182.
46. Van der Mooren M.J., Dmacker P.N.M., Thomas C.M.G., Rolland R. Beneficial effect of serum lipoproteins by 17β oestradiol-dydrogesterone therapy in postmenopausal women. Eur. J. Obstet. Gynaecol. Reprod. Biol. 47:1992;153-160.
47. Seed M., Sands R.H., McLaren M., Kirk G., Mandeno R., Darko D. The effect of hormone replacement therapy on selected cardiovascular risk factors in post menopausal women. Fam. Pract. 16:2000;497-505.
48. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20:1991;47-63.
49. Egeland G.M., Kuller L.H., Matthews K.A., Kelsey S.F., Cayley J., Guzick D. Pre menopausal determinants of menopausal estrogen use. Prev. Med. 20:1991;343-349.
50. Grodstein F., Stampfer M.J., Colditz G.A., et al. Post menopausal hormone therapy and mortality. New Engl. J. Med. 336:1997;1769-1775.
51. Sourander L., Rajala I., Raiha J., Makinen J., Erkkola R., Helenius H. Cardiovascular and cancer mortality and sudden cardiac death in post menopausal women on oestrogen replacement therapy. Lancet. 352:1998;1965-1969.
52. Westendorp I.C.D., Intveld B.A., Bolts M.L., Akkerhuls J.M., et al. Hormone replacement therapy and intima-media thickness of the common carotid artery: the Rottendam study. Stroke. 30:1999;2562-2567.
53. Hodis H., Mack W., Lobo R., Shoupe A., et al. Estrogen in the prevention of Atherosclerosis Trial (EPAT). Circulation. 102:2000;A4021.
54. Nguyen T., Hodge D., Lohse C., Heshmati H. Postmenopausal hormone replacement therapy, lipoprotein (a) and coronary heart disease events in a cohort of 2,853 healthy women. Circulation. 102:2000;A4022.
55. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghof E. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. New Engl. J. Med. 280:1998;605-613.
56. Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin. Trials. 19:1998;61-109.
57. Meade T.W. Hormone replacement therapy and haemostatic function. Thromb. Haemost. 78:1997;765-769.
58. Rees A. Less heat, more light. Curr. Opin. Lipidol. 10:1999;219-223.
59. Downs G.R., Clearfield M., Weiss S., et al. Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels; results of AFCPAS/TEXCAPS. Air Force/Texas coronary atherosclerosis study. J. Am. Med. Assoc. 279:1998;1615-1622.
60. The Lipid Research Clinics Coronary Primary Prevention Trial results. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351-64.
61. The Lipid Research Clinics Coronary Primary Prevention Trial results. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 1984;251:365-74.
62. Frick M.H., Elom O., Haapa K., et al. Helsinki Heart Study; primary prevention trial with gemfibrozil in middle aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl. J. Med. 31:(7):1987;1237-1245.
63. West of Scotland coronary prevention study; identification of high risk groups and comparison with other cardiovascular intervention trials. Lancet. 348:1996;1339-1342.
64. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(Suppl. 2):S1-29.
65. Smilde T., Trip M., Wollersheim H., van Wissen S., et al. Rational, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolaemia; The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. Clin. Drug Invest. 2:2000;67-79.
66. Gruchow H.W., Anderson A.F., Barboriak J.J., Sobocinski K.A. Post menopausal use of oestrogen and occlusion of coronary arteries. Am. Heart J. 115:1988;954-963.
67. McFarland K.F., Boniface M.E., Hornung C.A., Earnhardt W., et al. Risk factors and non contraceptive oestrogen use in women with and without coronary disease. Am. Heart J. 11:(7):1989;1209-1214.
68. Sullivan J.M., Van der Swaag R., Hughes J.P. Post menopausal estrogen use and coronary atherosclerosis. Ann. Intern. Med. 108:1988;258-263.
69. Hong M.K., Romm P.A., Reagan K., Green C.E., Rackley C.E. Effects of estrogen replacement therapy and serum lipid values and angiographically defined coronary artery disease in post menopausal women. Am. J. Cardiol. 69:1992;176-178.
70. O'Brien J.E., Peterson E., Keeler G.P., et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J. Am. Coll. Cardiol. 28:1996;1111-1118.
71. Sullivan J.M., Van der Swaag R., Hughes J.P., Maddock V., et al. Estrogen replacement and coronary heart disease: effect of survival in post menopausal women. Arch. Intern. Med. 150:1990;2557-2562.
72. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. New Engl. J. Med. 343:2000;522-529.
73. Miyagawa K., Rosch J., Staneczyk F., Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat. Med. 3:1997;324-327.
74. Adams M.R., Register T.C., Golden D.L., Wagner J.D., et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;217-221.
75. Lowe G., Woodward M., Vessey M., Rumley A., Gough P., Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Thromb. Haemost. 83:2000;530-535.
76. Herrington D.M., Vittinghoff E., Hunnighake D., Bittner V., et al. Effects of statin therapy on cardiovascular events and all cause mortality in women in the HERS. Circulation. 102:2000;S2 A4024.
77. Shlipak M.G., Simon J.A., Vittinghoff E., Lin F., et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. J. Am. Med. Assoc. 283:2000;1845-1852.
78. Simon T., Dukovic D., Jaillon P. Cardiovascular effects of Hormone replacement therapy in post menopausal women in CAPRIE: clopigrel versus aspirin in patients at risk of ischaemic events study. Circulation. 102:2000;S2 A4027.
79. Shlipak M., Go A.S., Angeja B., Frederick P., et al. The association of postmenopausal estrogen therapy with survival after myocardial infarction. Circulation. 102:2000;S2 A4023.
80. Darling G., Johns J., McCloud P., Davis S. Estrogen and progestin compared with simvastatin for hypercholesterolaemia in post menopausal women. New Engl. J. Med. 337:1997;595-601.
81. The Scandanavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandanavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-89.
82. Sacks F., Pfeffer M.A., Moye, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. New Engl. J. Med. 335:(14):1996;614-620.
83. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad base of initial cholesterol levels. New Engl. J. Med. 339:1998;1349-1357.
84. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of corollary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New Engl. J. Med. 341:1999;410-418.
85. McDonald C.C., Steward H.J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br. Med. J. 303:1991;435-437.
86. Rutqvist L.E., Mattson A. Cardiac and thromboembolic morbidity among post menopausal women with early stage breast cancer in a randomised trial of adjuvant tamoxifen. J. Natl. Cancer Inst. 85:1993;1398-1406.
87. De-Valk-de-Roo G.W., Stehouwer C.D., Meijer P., Mijatovic V., et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy post menopausal women; A two year, placebo controlled study. Arterioscler. Thromb. Vasc. Biol. 12:1999;2993-3300.
88. Potter S.M., Baum J.A., Teng H., Stillman R.I., Shay N.F., Erdman J.W. Jr. Soy protein and isofhavones: their effects on blood lipids and bone density in postmenopausal women. Am. J. Clin. Nutr. 68:1998;S1375-S1379.
89. Simons L.A., von Konigsmark M., Simons J., Cehermajer D.S. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am. J. Cardiol. 85:2000;1297-1301.